Retefast Kit

Retefast Kit Uses, Dosage, Side Effects, Food Interaction and all others data.

Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF).

Retefast Kit cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction.

Trade Name Retefast Kit
Availability Prescription only
Generic Reteplase
Reteplase Other Names Human t-PA (residues 1-3 and 176-527), Reteplasa, Reteplase, Reteplase, recombinant, Reteplase,recombinant
Related Drugs aspirin, lisinopril, metoprolol, propranolol, Plavix, Brilinta
Weight recombinant tissue plasminogen activator
Type Injection
Formula C1736H2671N499O522S22
Weight 39589.6 Da
Groups Approved, Investigational
Therapeutic Class
Manufacturer Cipla Limited
Available Country India
Last Updated: September 19, 2023 at 7:00 am
Retefast Kit
Retefast Kit

Uses

Retefast Kit is a purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.

For lysis of acute pulmonary emboli, intracoronary emboli, and management of myocardial infarction.

Retefast Kit is also used to associated treatment for these conditions: Acute Myocardial Infarction (AMI), Cardiovascular Mortality, Congestive Heart Failure (CHF)

How Retefast Kit works

Retefast Kit binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.

Food Interaction

  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Retefast Kit Hypertension interaction

[Major] The use of thrombolytics is contraindicated in patients with an active bleed (internal), trauma

Risk versus benefit should be carefully considered in the following conditions and thrombolytic therapy administered with caution in patients with recent (10 days) serious GI bleed or recent (10 days) surgical procedure (coronary bypass graft, obstetrical delivery, organ biopsy, puncture of noncompressible vessel), left heart thrombus, subacute bacterial endocarditis, hemostatic defect, CV disease, diabetic hemorrhagic retinopathy, or pregnancy.

Clinical monitoring of hematopoietic, bleeding and coagulation functions is recommended prior to initiation of thrombolytic therapy.

Measures of fibrinolytic activity and

Retefast Kit Disease Interaction

Major: bleeding risks

Innovators Monograph

You find simplified version here Retefast Kit

*** Taking medicines without doctor's advice can cause long-term problems.
Share